口服用氯胺酮快速治疗接受临终关怀患者的抑郁和焦虑。
Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.
机构信息
Institute for Palliative Medicine at San Diego Hospice, Palliative Care Psychiatry, San Diego, California 92103, USA.
出版信息
J Palliat Med. 2010 Jul;13(7):903-8. doi: 10.1089/jpm.2010.9808.
Abstract
Depression is prevalent and undertreated in patients receiving hospice care. Standard antidepressants do not work rapidly or often enough to benefit most of these patients. Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety. In addition, no adverse effects were noted. Further investigation with randomized, controlled clinical trials is necessary to firmly establish the effectiveness of oral ketamine for the treatment of depression and anxiety in patients receiving hospice care. Ketamine may be a promising safe, effective, and cost-effective rapid treatment for depression and anxiety in this population.
摘要
接受临终关怀的患者中普遍存在且未得到充分治疗的抑郁症。标准的抗抑郁药不能迅速或经常起效，无法使大多数患者受益。这里报告了两例病例，单次口服氯胺酮可迅速且适度地缓解抑郁和焦虑症状。此外，未观察到不良反应。需要进行随机对照临床试验的进一步研究，以确定口服氯胺酮治疗接受临终关怀的患者的抑郁和焦虑的有效性。氯胺酮可能是一种有前途的安全、有效且具有成本效益的快速治疗该人群抑郁和焦虑的方法。
相似文献
1
Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.口服用氯胺酮快速治疗接受临终关怀患者的抑郁和焦虑。
J Palliat Med. 2010 Jul;13(7):903-8. doi: 10.1089/jpm.2010.9808.
2
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.每日口服氯胺酮治疗接受临终关怀患者的抑郁和焦虑：一项 28 天的开放性概念验证试验。
J Palliat Med. 2013 Aug;16(8):958-65. doi: 10.1089/jpm.2012.0617. Epub 2013 Jun 27.
3
Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.氯胺酮用于临终关怀患者的抑郁症治疗：31例病例的回顾性病历审查
Psychosomatics. 2015 Jul-Aug;56(4):329-37. doi: 10.1016/j.psym.2014.05.005. Epub 2014 Jun 5.
4
Compounded oral ketamine.复方口服氯胺酮。
Int J Pharm Compd. 2012 Sep-Oct;16(5):364-8.
5
[Ketamine for treatment of acute depression].[氯胺酮用于治疗急性抑郁症]
Ugeskr Laeger. 2013 Sep 9;175(37):2090-3.
6
Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.口服氯胺酮增效治疗对难治性抑郁症和 PTSD 患者住院的影响：一项回顾性研究。
Psychopharmacology (Berl). 2018 Feb;235(2):393-398. doi: 10.1007/s00213-017-4786-3. Epub 2017 Nov 18.
7
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.鼻腔内依他佐辛辅助口服抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机临床试验。
JAMA Psychiatry. 2018 Feb 1;75(2):139-148. doi: 10.1001/jamapsychiatry.2017.3739.
8
Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.低剂量氯胺酮输注对焦虑与非焦虑抑郁的疗效：再探台湾治疗抵抗性抑郁症患者的辅助氯胺酮研究。
CNS Spectr. 2021 Aug;26(4):362-367. doi: 10.1017/S1092852920001194. Epub 2020 May 18.
9
Low-Dose Ketamine in Chronic Critical Illness.低剂量氯胺酮用于慢性危重病
J Intensive Care Med. 2016 Mar;31(3):216-20. doi: 10.1177/0885066615587868. Epub 2015 May 28.
10
New use for an old drug: oral ketamine for treatment-resistant depression.一种旧药的新用途：口服氯胺酮治疗难治性抑郁症。
BMJ Case Rep. 2016 Aug 3;2016:bcr2016216088. doi: 10.1136/bcr-2016-216088.
引用本文的文献
1
Use of ketamine for depression and suicidality in cancer and terminal patients: Review of current data.氯胺酮在癌症及终末期患者抑郁症和自杀倾向治疗中的应用：当前数据综述
AIMS Public Health. 2023 Jul 21;10(3):610-626. doi: 10.3934/publichealth.2023043. eCollection 2023.
2
A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).一项关于鼻内注射氯胺酮用于接受姑息治疗的癌症患者抑郁症的II期开放标签临床试验（INKeD-PC研究）。
Cancers (Basel). 2023 Jan 7;15(2):400. doi: 10.3390/cancers15020400.
3
Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review.氯胺酮治疗姑息治疗中抑郁症状的疗效和安全性：系统评价。
Braz J Psychiatry. 2023 May 11;45(2):182-195. doi: 10.47626/1516-4446-2022-2876.
4
Ketamine treatment for refractory anxiety: A systematic review.氯胺酮治疗难治性焦虑：系统评价。
Br J Clin Pharmacol. 2022 Oct;88(10):4412-4426. doi: 10.1111/bcp.15374. Epub 2022 May 20.
5
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.氯胺酮和其他谷氨酸受体调节剂治疗单相重性抑郁障碍成人患者的抑郁症。
Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3.
6
Could ketamine be the answer to treating treatment-resistant major depressive disorder?氯胺酮能否成为治疗难治性重度抑郁症的答案？
Gen Psychiatr. 2020 Aug 18;33(5):e100227. doi: 10.1136/gpsych-2020-100227. eCollection 2020.
7
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.单次和重复使用氯胺酮治疗单相和双相抑郁症的疗效：随机临床试验的荟萃分析。
Pharmacol Rep. 2020 Jun;72(3):543-562. doi: 10.1007/s43440-020-00097-z. Epub 2020 Apr 16.
8
Ketamine: A Review for Clinicians.氯胺酮：临床医生综述
Focus (Am Psychiatr Publ). 2018 Jul;16(3):243-250. doi: 10.1176/appi.focus.20180012. Epub 2018 Jul 16.
9
A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study.S-氯胺酮对姑息治疗患者焦虑的快速积极影响：一项回顾性试点研究。
BMC Palliat Care. 2020 Jan 3;19(1):1. doi: 10.1186/s12904-019-0499-1.
10
The Epidemiology of Depressive Symptoms in the Last Year of Life.生命最后一年抑郁症状的流行病学。
J Am Geriatr Soc. 2020 Feb;68(2):321-328. doi: 10.1111/jgs.16197. Epub 2019 Nov 5.
本文引用的文献
1
The opportunity for psychiatry in palliative care.姑息治疗中的精神病学机遇。
Can J Psychiatry. 2008 Nov;53(11):713-24. doi: 10.1177/070674370805301103.
2
Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer.静脉注射氯胺酮“冲击疗法”用于一名晚期癌症患者的难治性抑郁症治疗
J Palliat Med. 2008 Nov;11(9):1268-71. doi: 10.1089/jpm.2008.9828.
3
Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.重复静脉注射氯胺酮治疗治疗抵抗性重度抑郁症患者。
World J Biol Psychiatry. 2009;10(4 Pt 2):640-3. doi: 10.1080/15622970701420481.
4
Intravenous ketamine therapy in a patient with a treatment-resistant major depression.对一名难治性重度抑郁症患者进行静脉注射氯胺酮治疗。
Swiss Med Wkly. 2007 Apr 21;137(15-16):234-6. doi: 10.4414/smw.2007.11852.
5
Ketamine and the potential role for rapid-acting antidepressant medications.氯胺酮及速效抗抑郁药物的潜在作用。
Swiss Med Wkly. 2007 Apr 21;137(15-16):215-6. doi: 10.4414/smw.2007.11932.
6
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.作为第二步治疗的增效和换药策略中认知疗法与药物治疗的比较：STAR*D报告
Am J Psychiatry. 2007 May;164(5):739-52. doi: 10.1176/ajp.2007.164.5.739.
7
Depression and anxiety disorders in palliative cancer care.姑息性癌症护理中的抑郁症和焦虑症。
J Pain Symptom Manage. 2007 Feb;33(2):118-29. doi: 10.1016/j.jpainsymman.2006.07.016.
8
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.一项关于N-甲基-D-天冬氨酸拮抗剂治疗难治性重度抑郁症的随机试验。
Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856.
9
Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.两项关于重度抑郁症患者接受低剂量（亚麻醉剂量）氯胺酮输注的病例研究。
Pain Med. 2006 Jan-Feb;7(1):92-5. doi: 10.1111/j.1526-4637.2006.00101.x.
10
Use of methylphenidate in patients with cancer.哌甲酯在癌症患者中的应用。
Am J Hosp Palliat Care. 2006 Jan-Feb;23(1):35-40. doi: 10.1177/104990910602300106.
Zotero 插件